Related Experiment Video

Updated: May 5, 2026

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

9.9K

Histone deacetylases in cardiac fibrosis: current perspectives for therapy

Hui Tao1, Kai-Hu Shi1, Jing-Jing Yang2

  • 1Department of Cardiothoracic Surgery, The Second Hospital of Anhui Medical University, Hefei 230601, China; Cardiovascular Research Center, Anhui Medical University, Hefei 230601, China.

Cellular Signalling
|December 11, 2013
PubMed

Insights

Histone deacetylases (HDACs) are crucial in cardiac fibrosis, a key feature of heart disease. This review explores HDACs and their inhibitors as potential treatments for cardiac fibrosis by targeting fibroblast activation.

Area of Science:

  • Cardiovascular Biology
  • Molecular Biology
  • Epigenetics

Background:

  • Cardiac fibrosis is a significant pathological characteristic of cardiac remodeling in heart diseases.
  • The precise molecular mechanisms underlying cardiac fibrosis remain incompletely understood.
  • Histone deacetylases (HDACs) are enzymes critical for regulating gene transcription through chromatin remodeling.

Purpose of the Study:

  • To review the innovative aspects of HDACs concerning their biogenesis and role in cardiac fibrosis.
  • To discuss the association between HDAC activity and the development/progression of cardiac fibrosis.
  • To explore the therapeutic potential of HDAC inhibitors in treating cardiac fibrosis.

Main Methods:

  • Literature review focusing on HDACs and cardiac fibrosis.
  • Analysis of studies investigating HDACs' role in fibroblast activation and proliferation.
  • Synthesis of current knowledge on HDAC inhibitors' efficacy.

Main Results:

  • HDACs play essential roles in regulating gene transcription and are implicated in cardiac fibrosis.
  • HDAC activity is demonstrably linked to the initiation and progression of cardiac fibrosis.
  • HDAC inhibitors show promise as a therapeutic strategy for cardiac fibrosis.

Conclusions:

  • HDACs are key regulators in the development of cardiac fibrosis.
  • Targeting HDACs with inhibitors offers a potential therapeutic avenue for heart diseases characterized by fibrosis.
  • Further research into HDACs and their inhibitors could lead to novel treatments for cardiac fibrosis.

Keywords:
Cardiac fibrosisECMEpigeneticExtracellular matrixFGFFibroblastFibroblast growth factorHATsHDACsHistone acetyltransferasesHistone deacetylaseHistone deacetylasesHistone deacetylationIGF-II/mannose 6-phosphate receptorIGF-IIR/Man-6-PMEF2Myocyte enhancer factor-2NRVMsNeonatal rat ventricular myocytesPDGFPKD1Platelet-derived growth factorProliferationProtein kinase D1TGF-β1TIMPsTissue inhibitors of matrix metalloproteinasesTransforming growth factor β1α-SMAα-smooth muscle actin

More Related Videos

Assessing Cardiac Reprogramming using High Content Imaging Analysis06:02

Assessing Cardiac Reprogramming using High Content Imaging Analysis

Published on: October 26, 2020

790
Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes09:16

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes

Published on: June 3, 2018

6.8K

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
753
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.9K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.9K
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
805
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
626
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.8K